Table 2.

Comparison of AZ pharmacokinetic parameter estimates in HIV-1-infected and non-HIV-1-infected children

Group and infection (regimen)No. of subjectsMean ± SD (range)
Cmax (ng/ml)CSS(ng/ml)Tmax (h)AUC0–24(ng · h/ml)CL/ F (liters/h/kg)
HIV infected (5 mg/kg q.d.)7230 ± 130 (48–447) 91 ± 66 (28–222)2.0 ± 1.02,329 ± 1,632 (695–5,561)3.04 ± 1.96 (0.93–6.95)
Non-HIV infected
 Acute otitis mediaa (day 1, 10 mg/kg; days 2–5, 5 mg/kg q.d.b)13224 ± 120 (65–496) 77 ± 27d(40–110)1.8 ± 0.41,841 ± 651 (951–2,646)3.03 ± 1.28d (1.82–6.10)
 Streptococcal pharyngitisc (day 1, 10 mg/kg; days 2–5, 5 mg/kg q.d.)14383 ± 142 (165–623)130 ± 43d(44–214)2.4 ± 1.13,109 ± 1,033 (1,062–5,134)1.89 ± 1.01d(0.84–4.90)
  • a Data are from reference 14.

  • b q.d., once a day.

  • c Data are from reference 13.

  • d Values are estimated based on dose and/or AUC0–24 data provided in the reference.